Efficacy and safety of phosphate binders, ferric citrete hydrate and lanthunam carbohydrate, in patients undergoing maintenance hemodialysis

Efficacy and safety of phosphate binders, ferric citrete hydrate and lanthunam carbohydrate, in patients undergoing maintenance hemodialysis - Efficacy of phosphate binders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021818

Enrollment

Registered

2016-04-07

Start date

2016-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are undergoing maintenance hemodialysis

Interventions

ferric citrate hydrate or sucroferric oxyhydroxide for 6 months continue to take lanthanum hydrate carabonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) age > 19 years and < 86 years, (2) hemodialysis duration >2 years at enrollment, and (3) hyperphosphatemia that was treated with lanthanum carbonate at least 12 weeks before enrollment.

Exclusion criteria

Exclusion criteria: (1) Active gastrointestinal hemorrhage,(2) malignant tumor, (3) liver cirrhosis and (4) hematological disorder.

Design outcomes

Primary

Measure	Time frame
Serum FGF23 levels, dosage of ESA and iron metabolism	—

Secondary

Measure	Time frame
Ca, P, and intact-PTH levels	—

Countries

Japan

Contacts

Public ContactTomoyasu Otsuki

Nihon University School of Medicine Divisions of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine

totsuki16@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026